Indian Journal of Medical Biochemistry

Register      Login

VOLUME 24 , ISSUE 3 ( September-December, 2020 ) > List of Articles

Original Article

Serum CA-125 and Serum CEA Ratio to Distinguish between Ovarian Malignancies and Non-ovarian Malignancies

Anju Radhakrishnan, Neeta Malukar, Shilpa Jain

Keywords : Cancer antigen 125, Cancer antigen 125 to carcinoembryonic antigen ratio, Epithelial ovarian malignancies

Citation Information : Radhakrishnan A, Malukar N, Jain S. Serum CA-125 and Serum CEA Ratio to Distinguish between Ovarian Malignancies and Non-ovarian Malignancies. Indian J Med Biochem 2020; 24 (3):96-98.

DOI: 10.5005/jp-journals-10054-0161

License: CC BY-NC 4.0

Published Online: 01-12-2020

Copyright Statement:  Copyright © 2020; The Author(s).


Introduction: Globally, ovarian carcinoma is the 7th most common cancer. Cancer antigen 125 (CA-125) is the most frequently used biomarker for ovarian cancer (OC). Carcinoembryonic antigen (CEA) is present only at very low levels in healthy adults and is raised in colon cancer, pancreatic malignancies, pancreatitis, cirrhosis, etc. The present study is to evaluate the ability of CEA in combination with CA-125 to differentiate epithelial ovarian malignancies from non-ovarian malignancies. Aims and objectives: To study, compare, and calculate the ratio of serum CA-125 and serum CEA levels in cases of epithelial ovarian malignancies and non-ovarian malignancies. Materials and methods: Thirty patients of epithelial ovarian malignancies in group I and 30 female patients of non-ovarian malignancies in group II are included. Results: Specificity and positive predictive value (PPV) increase when CA-125 to CEA ratio increases and both are 100% if the ratio is >50. When CEA (<5 ng/mL) alone is used for distinguishing an ovarian malignancy from a non-ovarian malignancy, sensitivity is only 93%, specificity 67%, PPV 74%, negative predictive value (NPV) 91%, respectively. Conclusion: When CA-125/CEA ratio increases, the sensitivity and NPV fall but the specificity and PPV increase and became 100% when it is >50. By knowing the ratio we can have an early diagnosis of OC. We cannot always consider the cut-off for CEA as <5 ng/mL because in smokers the reference value is up to 10 ng/mL.

  1. World Cancer Report 2014, ch. 5.12. World Health Organization; 2014. p. 467.
  2. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101(1):3–27. DOI: 10.1002/cncr.20288.
  3. DeSantis CE, Miller KD, Dale W, et al. Cancer statistics for adults aged 85 years and older. CA Cancer J Clin 2019;69(6):452–467. DOI: 10.3322/caac.21577.
  4. Oronsky B, Ray CM, Spira AI, et al. A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer. Med Oncol 2017;34(6):103. DOI: 10.1007/s12032-017-0960-z.
  5. Chandra A, Pius C, Nabeel M, et al. Ovarian cancer: current status and strategies for improving therapeutic outcomes. Cancer Med 2019;8(16):7018–7031. DOI: 10.1002/cam4.2560.
  6. De Angelis R. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 2014;15(1):23–34. DOI: 10.1016/S1470-2045(13)70546-1.
  7. Nathalie Scholler Nicole Urban. CA125 in ovarian cancer. Biomark Med 2007;1(4):513–523. DOI: 10.2217/17520363.1.4.513.
  8. Boehm MK, Perkins SJ. Structural models for carcinoembryonic antigen and its complex with the single-chain Fv antibody molecule MFE23. FEBS Lett 2000;475(1):11–16. DOI: 10.1016/S0014-5793(00)01612-4.
  9. Buamah PK, Rake MO, Drake SR, et al. Serum CA12-5 concentrations and CA12-5/CEA ratios in patients with epithelial ovarian cancer. J Surg Oncol 1990;44(2):97–99. DOI: 10.1002/jso.2930440207.
  10. Yedema CA, Kenemans P, Wobbes T, et al. Use of serum tumour markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. Tumour Biol 1992;13(1-2):18–26. DOI: 10.1159/000217748.
  11. Sorensen SS, Mosgaard BJ. Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis. Dan Med Bull 2011;58(11):A4331.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.